The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design
Open accessAbstract
Pyridine-based ring systems are one of the most extensively used heterocycles in the field of drug design, primarily due to their profound effect on pharmacological activity, which has led to the discovery of numerous broad-spectrum therapeutic agents. In the US FDA database, there are 95 approved pharmaceuticals that stem from pyridine or dihydropyridine, including isoniazid and ethionamide (tuberculosis), delavirdine (HIV/AIDS), abiraterone acetate (prostate cancer), tacrine (Alzheimer's), ciclopirox (ringworm and athlete's foot), crizotinib (cancer), nifedipine (Raynaud's syndrome and premature birth), piroxicam (NSAID for arthritis), nilvadipine (hypertension), roflumilast (COPD), pyridostigmine (myasthenia gravis), and many more. Their remarkable therapeutic applications have encouraged researchers to prepare a larger number of biologically active compounds decorated with pyridine or dihydropyridine, expandeing the scope of finding a cure for other ailments. It is thus anticipated that myriad new pharmaceuticals containing the two heterocycles will be available in the forthcoming decade. This review examines the prospects of highly potent bioactive molecules to emphasize the advantages of using pyridine and dihydropyridine in drug design. We cover the most recent developments from 2010 to date, highlighting the ever-expanding role of both scaffolds in the field of medicinal chemistry and drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vitaku, E., Smith, D. T., & Njardarson, J. T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501100b · Cited by 6,418
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Myasthenia gravis: subgroup classification and therapeutic strategies
Gilhus, N. E., & Verschuuren, J. J. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00145-3 · Cited by 1,267
Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture
Yang, Y.-X., Lewis, J. D., Epstein, S., & Metz, D. C. (2006) · JAMA · doi:10.1001/jama.296.24.2947 · Cited by 1,214
Cerebral Arterial Spasm – A Controlled Trial of Nimodipine in Patients with Subarachnoid Hemorrhage
Allen, G. S., Ahn, H. S., Preziosi, T. J., Battye, R., Boone, S. C., Chou, S. N., Kelly, D. L., Weir, B. K., Crabbe, R. A., Lavik, P. J., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198303173081103 · Cited by 1,195
Dyslipidemia in type 2 diabetes mellitus
Mooradian, A. D. (2009) · Nature Reviews Endocrinology · doi:10.1038/ncpendmet1066 · Cited by 1,042
NAD+ metabolism in health and disease
Belenky, P., Bogan, K. L., & Brenner, C. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.11.006 · Cited by 981
Inflammation in CNS neurodegenerative diseases
Stephenson, J., Nutma, E., van der Valk, P., & Amor, S. (2018) · Immunology · doi:10.1111/imm.12922 · Cited by 966
Bull, J. A., Mousseau, J. J., Pelletier, G., & Charette, A. B. (2012) · Chemical Reviews · doi:10.1021/cr200251d · Cited by 920
Cited by
Šikorová, E., Štěpánková, Š., Frýbová, E., Konečná, K., Korbielová, J., Švarcová, M., Janďourek, O., Pflégr, V., Bősze, S., & Krátký, M. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70188 · Cited by 3
Metadata
- Authors
- Ling, Y., Hao, Z.-Y., Liang, D., Zhang, C.-L., Liu, Y.-F., & Wang, Y.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2021-10
- Volume
- Volume 15
- Pages
- 4289-4338
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W3205136031
- Cited by
- 414
- References
- 143
- FWCI
- 21.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design. https://app.cochat.ai/papers/10.2147/dddt.s329547
- The paper
- Ling, Y., Hao, Z.-Y., Liang, D., Zhang, C.-L., Liu, Y.-F., & Wang, Y. (2021). The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s329547
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
